Ankerst DP - Search Results

1

Prediction of future risk of any and higher-grade prostate cancer based on the PLCO and SELECT trials.

Gelfond JA, Hernandez B, Goros M, Ibrahim JG, Chen MH, Sun W, Leach RJ, Kattan MW, Thompson IM, Ankerst DP, Liss M. Gelfond JA, et al. Among authors: ankerst dp. BMC Urol. 2022 Mar 26;22(1):45. doi: 10.1186/s12894-022-00986-w. BMC Urol. 2022. PMID: 35351104 Free PMC article.

2

Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.

Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ, Parnes HL, Coltman CA Jr. Thompson IM, et al. Among authors: ankerst dp. JAMA. 2005 Jul 6;294(1):66-70. doi: 10.1001/jama.294.1.66. JAMA. 2005. PMID: 15998892

3

Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial.

Etzioni RD, Howlader N, Shaw PA, Ankerst DP, Penson DF, Goodman PJ, Thompson IM. Etzioni RD, et al. Among authors: ankerst dp. J Urol. 2005 Sep;174(3):877-81. doi: 10.1097/01.ju.0000169255.64518.fb. J Urol. 2005. PMID: 16093979 Clinical Trial.

4

Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial.

Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, Feng Z, Parnes HL, Coltman CA Jr. Thompson IM, et al. Among authors: ankerst dp. J Natl Cancer Inst. 2006 Apr 19;98(8):529-34. doi: 10.1093/jnci/djj131. J Natl Cancer Inst. 2006. PMID: 16622122

5

Obesity, adipokines, and prostate cancer in a prospective population-based study.

Baillargeon J, Platz EA, Rose DP, Pollock BH, Ankerst DP, Haffner S, Higgins B, Lokshin A, Troyer D, Hernandez J, Lynch S, Leach RJ, Thompson IM. Baillargeon J, et al. Among authors: ankerst dp. Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1331-5. doi: 10.1158/1055-9965.EPI-06-0082. Cancer Epidemiol Biomarkers Prev. 2006. PMID: 16835332

6

Effect of finasteride on the sensitivity of PSA for detecting prostate cancer.

Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman SM, Lucia MS, Parnes HL, Coltman CA Jr. Thompson IM, et al. Among authors: ankerst dp. J Natl Cancer Inst. 2006 Aug 16;98(16):1128-33. doi: 10.1093/jnci/djj307. J Natl Cancer Inst. 2006. PMID: 16912265 Clinical Trial.

7

External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population.

Parekh DJ, Ankerst DP, Higgins BA, Hernandez J, Canby-Hagino E, Brand T, Troyer DA, Leach RJ, Thompson IM. Parekh DJ, et al. Among authors: ankerst dp. Urology. 2006 Dec;68(6):1152-5. doi: 10.1016/j.urology.2006.10.022. Urology. 2006. PMID: 17169636

8

Understanding mixed messages about prostate specific antigen: biases in the evaluation of cancer biomarkers.

Ankerst DP, Thompson IM. Ankerst DP, et al. J Urol. 2007 Feb;177(2):426-7. doi: 10.1016/j.juro.2006.11.009. J Urol. 2007. PMID: 17222602 No abstract available.

9

Sensitivity and specificity of prostate-specific antigen for prostate cancer detection with high rates of biopsy verification.

Ankerst DP, Thompson IM. Ankerst DP, et al. Arch Ital Urol Androl. 2006 Dec;78(4):125-9. Arch Ital Urol Androl. 2006. PMID: 17269614 Clinical Trial.

10

Merging digital rectal exam, family history, age and prostate-specific antigen to create a decision-making tool.

Ankerst DP, Thompson IM. Ankerst DP, et al. Arch Ital Urol Androl. 2006 Dec;78(4):143-6. Arch Ital Urol Androl. 2006. PMID: 17269618

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

148 results

Search Page